Beacon Equity issues Technical Trading Overview for Arena Pharmaceuticals Inc.
The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
(EMAILWIRE.COM, September 23, 2009 ) DALLAS, Texas - BeaconEquity.com announces an investment report featuring pharmaceutical company Arena Pharmaceuticals Inc. (Nasdaq: ARNA).
The investment report on Arena Pharmaceuticals Inc. (Nasdaq: ARNA) should be of particular interest to other health care companies: Abbott Laboratories (NYSE: ABT), Sanofi-Aventis (NYSE: SNY) and Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA).
It is available at: http://www.beaconequity.com/i/ARNA
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Arena Pharmaceutical Inc. (ARNA) engages in the development of innovative therapies for the treatment of cardiovascular, central nervous system, inflammatory and metabolic diseases. The Company's lead drug therapy candidate Lorcaserin Hydrochloride is in phase III for the treatment of obesity. Pipeline drug candidates developed by the Company target G protein-coupled receptors (GPCRs), a new approach of compounds presently evaluated in conjunction with Merck & Co. Inc. and Ortho-McNeil-Janssen Pharmaceuticals Inc.
In the report, the analyst notes:
“If ultimately approved by the U.S. Food and Drug Administration (FDA), the market for ARNA’s drug candidate Lorcaserin Hydrochloride could reach $500 million to more than $1 billion at its market saturation. Lorcaserin Hydrochloride is in phase III clinical trials, with the prospects of reaching commercialization reaching approximately 90% following successful completion of this phase of development.
“APD791, an anti-thrombotic drug candidate, passed phase Ia and phase Ib clinical trials. The target population for this drug candidate totals more than 13.9 million Americans who have survived either a heart attack or a stroke. Other drug candidates in development include APD916 & APD811.”
To read the entire report visit: http://www.beaconequity.com/i/ARNA
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
The investment report on Arena Pharmaceuticals Inc. (Nasdaq: ARNA) should be of particular interest to other health care companies: Abbott Laboratories (NYSE: ABT), Sanofi-Aventis (NYSE: SNY) and Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA).
It is available at: http://www.beaconequity.com/i/ARNA
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Arena Pharmaceutical Inc. (ARNA) engages in the development of innovative therapies for the treatment of cardiovascular, central nervous system, inflammatory and metabolic diseases. The Company's lead drug therapy candidate Lorcaserin Hydrochloride is in phase III for the treatment of obesity. Pipeline drug candidates developed by the Company target G protein-coupled receptors (GPCRs), a new approach of compounds presently evaluated in conjunction with Merck & Co. Inc. and Ortho-McNeil-Janssen Pharmaceuticals Inc.
In the report, the analyst notes:
“If ultimately approved by the U.S. Food and Drug Administration (FDA), the market for ARNA’s drug candidate Lorcaserin Hydrochloride could reach $500 million to more than $1 billion at its market saturation. Lorcaserin Hydrochloride is in phase III clinical trials, with the prospects of reaching commercialization reaching approximately 90% following successful completion of this phase of development.
“APD791, an anti-thrombotic drug candidate, passed phase Ia and phase Ib clinical trials. The target population for this drug candidate totals more than 13.9 million Americans who have survived either a heart attack or a stroke. Other drug candidates in development include APD916 & APD811.”
To read the entire report visit: http://www.beaconequity.com/i/ARNA
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Contact Information:
Beacon Equity
Jeff Bishop
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Beacon Equity
Jeff Bishop
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
|
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International Equityallianceir.com Penny Stocks to Watch Sign up for hot penny stock picks Gains of 500%+ possible! Premiumstockpicks.com/landing/ Your text Ads & PR Text Ads plus unlimited press releases, One release featured/Day for only $575 per month. Read more on Text Ads & PR Your text Ads Here! Text Ads are only $289 per month. Ads are placed same day. More on Text Ads Advertising |